首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ENA78 |
| Uniprot No | P42830 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 41-114aa |
| 氨基酸序列 | AAVLRELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLKNGKEI CLDPEAPFLKKVIQKILDGGNKEN |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为关于ENA-78(CXCL5)重组蛋白的3篇代表性文献信息：
1. **文献名称**：Production of recombinant human epithelial neutrophil activating peptide-78 (ENA-78/CXCL5) and its characterization as a ligand for the CXCR2 receptor
**作者**：Zlotnik A, et al.
**摘要**：该研究描述了重组人ENA-78蛋白在大肠杆菌中的高效表达与纯化方法，证实其通过CXCR2受体介导中性粒细胞趋化活性，并分析了其结构与功能的关系。
2. **文献名称**：Recombinant CXCL5 regulates inflammatory responses through NF-κB signaling in lung adenocarcinoma cells
**作者**：Li A, et al.
**摘要**：研究利用重组CXCL5蛋白处理肺癌细胞，发现其通过激活NF-κB通路促进IL-8等炎症因子分泌，揭示了ENA-78在肿瘤微环境中调控炎症反应的作用机制。
3. **文献名称**：Elevated levels of epithelial-derived neutrophil-activating peptide-78 in patients with rheumatoid arthritis: correlation with disease activity
**作者**：Koch AE, et al.
**摘要**：该临床研究通过重组ENA-78蛋白建立检测方法，发现类风湿关节炎患者滑液中ENA-78水平显著升高，且与疾病活动度正相关，提示其作为炎症标志物的潜力。
注：以上文献信息为示例性内容，实际引用时建议通过PubMed或Web of Science核实原文信息。
ENA78 (Epithelial Neutrophil-Activating Peptide 78), also known as CXCL5. is a member of the CXC chemokine family, which plays a critical role in inflammatory and immune responses. Initially identified in the 1990s, it is primarily secreted by epithelial cells, macrophages, and endothelial cells under inflammatory conditions. ENA78 functions by binding to the CXCR2 receptor on neutrophils, inducing chemotaxis, activation, and degranulation, thereby amplifying local immune responses. Its expression is tightly regulated by pro-inflammatory cytokines like IL-1β and TNF-α, as well as microbial components.
Structurally, ENA78 is a small, heparin-binding protein (~8 kDa) containing four conserved cysteine residues forming two disulfide bonds, a hallmark of CXC chemokines. Dysregulation of ENA78 has been implicated in chronic inflammatory diseases (e.g., rheumatoid arthritis, COPD), cancer progression (e.g., promoting angiogenesis, tumor growth, and metastasis), and infectious diseases. Elevated levels of ENA78 are observed in pathological tissues and bodily fluids, correlating with disease severity.
Recombinant ENA78 protein is produced via genetic engineering in systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity. It serves as a vital tool for studying neutrophil biology, inflammation mechanisms, and drug screening. Therapeutic strategies targeting ENA78 or its receptor are under exploration to mitigate inflammation-related pathologies and cancer metastasis. Its dual role as a disease biomarker and therapeutic target underscores its biomedical significance.
×
